A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (EOC) (OV.16). A Gynecologic Cancer Intergroup Study of the NCIC CTG, EORTC GCG, and GEICO

Published 2017 View Full Article

Authors

Keywords

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 26, Issue 15_suppl, Pages LBA5505-LBA5505

Publisher

American Society of Clinical Oncology (ASCO)

Online

2017-02-24

DOI

10.1200/jco.2008.26.15_suppl.lba5505

Ask authors/readers for more resources

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

JOURNAL OF CLINICAL ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Create your own webinar

Ask a Question. Answer a Question.